Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3b Study for Management of Ocular Side Effects in Subjects With EGFR-amplified Glioblastoma Receiving Depatuxizumab Mafodotin (ABT-414)

Trial Profile

Phase 3b Study for Management of Ocular Side Effects in Subjects With EGFR-amplified Glioblastoma Receiving Depatuxizumab Mafodotin (ABT-414)

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 12 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Depatuxizumab mafodotin (Primary) ; Steroids; Temozolomide; Vasoconstrictors
  • Indications Glioblastoma; Gliosarcoma
  • Focus Adverse reactions; Registrational
  • Acronyms UNITE Study
  • Sponsors AbbVie; AbbVie Germany

Most Recent Events

  • 19 Mar 2021 Status changed from completed to discontinued because clinical development of depatuxizumab mafodotin inglioblastoma was stopped due to lack of survival benefit.
  • 31 Oct 2020 This trial has been Suspended in Netherlands, according to European Clinical Trials Database record.
  • 02 Apr 2020 Status changed from suspended to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top